Chemotherapy Plus Immunotherapy Combined With SBRT as Neoadjuvant Therapy for Patients With Resectable NSCLC
Clinical trial NCT06718309 · RECRUITING
Trial details
- NCT number
- NCT06718309
- Sponsor
- First People's Hospital of Hangzhou
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-04-24
- Primary completion
- 2027-04-30
- Enrollment
- 40
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.